Gene Biotherapeutics Inc
OTC:CRXM

Watchlist Manager
Gene Biotherapeutics Inc Logo
Gene Biotherapeutics Inc
OTC:CRXM
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 64.9 USD

Intrinsic Value

CRXM latest financial reports are more than 2 years old.
CRXM doesn't have a meaningful market cap.

There is not enough data to reliably calculate the intrinsic value of CRXM.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CRXM Intrinsic Value
Not Available
Base Case Scenario
Compare CRXM to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CRXM?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gene Biotherapeutics Inc

Current Assets 410.6k
Cash & Short-Term Investments 386k
Other Current Assets 24.6k
Non-Current Assets 156.4k
PP&E 149.3k
Other Non-Current Assets 7.1k
Current Liabilities 5m
Accounts Payable 745.6k
Accrued Liabilities 3.2m
Other Current Liabilities 1.1m
Non-Current Liabilities -585.3k
Long-Term Debt 26.2k
Other Non-Current Liabilities -611.5k
Efficiency

Free Cash Flow Analysis
Gene Biotherapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Gene Biotherapeutics Inc

Revenue
0 USD
Operating Expenses
-1.3m USD
Operating Income
-1.3m USD
Other Expenses
744.3k USD
Net Income
-517.9k USD
Fundamental Scores

CRXM Profitability Score
Profitability Due Diligence

Gene Biotherapeutics Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional ROIC
Positive ROE
Declining ROE
55/100
Profitability
Score

Gene Biotherapeutics Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

CRXM Solvency Score
Solvency Due Diligence

Gene Biotherapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
29/100
Solvency
Score

Gene Biotherapeutics Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRXM Price Targets Summary
Gene Biotherapeutics Inc

There are no price targets for CRXM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CRXM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y